Pazopanib for metastatic soft-tissue sarcoma: A multicenter retrospective study

Basit Öğe Kaydı
dc.authoridHacioglu, Bekir/0000-0001-8490-3239
dc.authoridBeşiroğlu, Mehmet/0000-0002-1171-8320
dc.authorwosidHacioglu, Bekir/GZH-1824-2022
dc.authorwosidDogu, Gamze Gokoz/A-9815-2010
dc.authorwosidozcelik, melike/AAS-7557-2020
dc.authorwosidBeşiroğlu, Mehmet/AEQ-3080-2022
dc.contributor.authorKoca, Sinan
dc.contributor.authorBesiroglu, Mehmet
dc.contributor.authorOzcelik, Melike
dc.contributor.authorKaraca, Mustafa
dc.contributor.authorBilici, Mehmet
dc.contributor.authorHacioglu, Bekir
dc.contributor.authorDogu, Gamze G.
dc.date.accessioned2024-08-04T20:47:18Z
dc.date.available2024-08-04T20:47:18Z
dc.date.issued2021
dc.departmentİnönü Üniversitesien_US
dc.description.abstractPurpose Soft tissue sarcomas are associated with a poor prognosis and low chemotherapeutic efficiency. Pazopanib is an orally available multi-tyrosine kinase inhibitor that was explored in patients with non-adipocytic advanced soft tissue sarcomas. The aim of this retrospective study was to evaluate the real life data of single-agent pazopanib efficacy and safety for soft tissue sarcomas in the Turkish population. Materials and methods We evaluated a total of 103 patients (41 males, 62 females) who received pazopanib for advanced non-adipocytic soft tissue sarcomas diagnosis in eight centers of Turkey, retrospectively. The pazopanib dose was 800 mg once daily. Progression-free survival, overall survival, and adverse events were analyzed. Results The median age was 50 years (range, 38-58). Majority of the patients had leimyosarcoma (41%). Median progression-free survival was 4.3 months, and the median overall survival was 10.1 months. The main common toxicities were fatigue, anorexia, weight loss, nausea, hypertension, and grade >= 3 toxicities were fatigue, anorexia, weight loss, and liver disorder. Conclusion Pazopanib is an efficient and tolerable agent and is well tolerated in good performance status patients with relapsed, advanced non-adipocytic soft tissue sarcomas.en_US
dc.identifier.doi10.1177/1078155220924075
dc.identifier.endpage546en_US
dc.identifier.issn1078-1552
dc.identifier.issn1477-092X
dc.identifier.issue3en_US
dc.identifier.pmid32419618en_US
dc.identifier.scopus2-s2.0-85084830817en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage541en_US
dc.identifier.urihttps://doi.org/10.1177/1078155220924075
dc.identifier.urihttps://hdl.handle.net/11616/99288
dc.identifier.volume27en_US
dc.identifier.wosWOS:000534051900001en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherSage Publications Ltden_US
dc.relation.ispartofJournal of Oncology Pharmacy Practiceen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectPazopaniben_US
dc.subjectsoft tissue sarcomaen_US
dc.subjecttargeted therapyen_US
dc.titlePazopanib for metastatic soft-tissue sarcoma: A multicenter retrospective studyen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu